Andrea Wahner Hendrickson
Overview
Explore the profile of Andrea Wahner Hendrickson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Berchuck A, Backes F, Cohen J, Grisham R, Leath C, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):512-519.
PMID: 39413835
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of...
2.
Rimel B, Enserro D, Bender D, Gunderson Jackson C, Tan A, Alluri N, et al.
Cancer
. 2023 Dec;
130(8):1234-1245.
PMID: 38127487
Purpose: This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced...
3.
Armstrong D, Alvarez R, Backes F, Bakkum-Gamez J, Barroilhet L, Behbakht K, et al.
J Natl Compr Canc Netw
. 2022 Sep;
20(9):972-980.
PMID: 36075393
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines...
4.
Grudem M, Hendrickson A
J Adv Pract Oncol
. 2021 Feb;
11(3):297-300.
PMID: 33598329
Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on...
5.
Colon-Otero G, Zanfagnin V, Hou X, Foster N, Asmus E, Hendrickson A, et al.
ESMO Open
. 2020 Oct;
5(5):e000926.
PMID: 33109627
Objective: We describe a phase II clinical trial of the combination of ribociclib and letrozole for treatment of relapsed oestrogen receptor (ER)-positive ovarian cancer (OC) and endometrial cancer (EC). The...
6.
Marshall A, Dines V, Hendrickson A, Warsame R, Thanarajasingam G, Thompson C, et al.
Womens Health (Lond)
. 2020 Sep;
16:1745506520949417.
PMID: 32990525
Background: Parenthood during medical training is common and impacts trainee well-being. However, current graduate medical education parental health policies are often limited in scope. We explored current fellowship trainees' knowledge...
7.
Smith C, Hendrickson A, Grudem M, Klampe C, Deering E, Jatoi A
Am J Hosp Palliat Care
. 2019 Jul;
37(3):235-238.
PMID: 31315424
Background: Seventy percentage of patients who receive paclitaxel have diffuse, refractory myalgias, and arthralgias. Based on anecdotal reports, this study explored whether loratadine, an antihistamine, palliates these symptoms. Methods: The...
8.
Balko R, Hendrickson A, Grudem M, Klampe C, Jatoi A
Am J Hosp Palliat Care
. 2018 Jul;
36(1):72-75.
PMID: 29983087
Background:: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class...
9.
Jatoi A, Breitkopf C, Foster N, Block M, Grudem M, Hendrickson A, et al.
Oncology
. 2014 Dec;
88(4):208-13.
PMID: 25502607
Purpose: This trial was undertaken (1) to determine the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with the protein kinase C iota (PKCι) inhibitor...
10.
Lewis M, Hendrickson A, Moynihan T
CA Cancer J Clin
. 2011 Aug;
61(5):287-314.
PMID: 21858793
Oncologic emergencies can occur at any time during the course of a malignancy, from the presenting symptom to end-stage disease. Although some of these conditions are related to cancer therapy,...